双侧肾上腺转移对177Lu-PSMA治疗近完全缓解的病例报告
一例72岁去势抵抗性前列腺腺癌患者,因化疗期间PSA显著升高行68Ga-PSMA-11 PET/CT再分期,发现双侧肾上腺高摄取,经MRI和肾上腺活检确诊为肾上腺转移。患者为寡转移、对既往系统治疗难治且不适合手术或放疗,遂启动177Lu-PSMA-617放射性配体治疗;四个周期后PSA逐步下降,治疗后SPECT/CT随访显示肾上腺和骨转移近完全缓解,无治疗相关不良反应。
要点
- 68Ga-PSMA-11 PET/CT可检出前列腺癌罕见肾上腺转移。
- 177Lu-PSMA-617治疗四周期后PSA逐步下降。
- 治疗后SPECT/CT示肾上腺和骨转移近完全缓解,无治疗相关不良反应。
核心结论
- 去势抵抗性前列腺癌双侧肾上腺转移对177Lu-PSMA-617治疗达到近完全缓解。
研究设计与样本
- 单例病例报告:72岁去势抵抗性前列腺腺癌患者,因化疗期间PSA显著升高行68Ga-PSMA-11 PET/CT再分期。
主要发现
- 68Ga-PSMA-11 PET/CT示双侧肾上腺高摄取,前列腺和少量硬化性骨病灶亦有摄取。
- MRI及肾上腺活检证实肾上腺转移。
- 177Lu-PSMA-617治疗四周期后PSA逐步下降。
- 治疗后SPECT/CT随访示肾上腺和骨转移近完全缓解,无治疗相关不良反应。
临床怎么用
- 对寡转移、既往系统治疗难治且不适合手术或放疗的去势抵抗性前列腺癌患者,可考虑177Lu-PSMA-617放射性配体治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 72-year-old man with castration-resistant prostate adenocarcinoma underwent 68Ga-PSMA-11 PET/CT for restaging due to significantly increased PSA levels during chemotherapy. Imaging revealed high 68Ga-PSMA-11 uptake in bilateral adrenal uptake, with additional uptake in the prostate and few sclerotic bone lesions. MRI and afterwards adrenal gland biopsy confirmed adrenal metastases, an uncommon metastatic site. As the patient was oligometastatic, refractory to previous systemic therapies, and ineligible for surgery or radiotherapy, 177Lu-PSMA-617 radioligand therapy was initiated. After four treatment cycles, PSA levels progressively decreased, and post-therapeutic follow-up SPECT/CT demonstrated a near-complete response in adrenal and bone metastases without treatment-related adverse effects.
引用
- Yilmaz B, Ozkanli G, Özcan E, et al. Near-complete Response of Bilateral Adrenal Metastases to 177Lu-PSMA Therapy in Castration-resistant Prostate Cancer on Posttherapeutic SPECT-CT Follow Up. Clin Nucl Med. 2026. PMID: 42853992. doi:10.1097/RLU.0000000000006648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。